Market Research Logo

Minimally Invasive Spinal Implant Market Report Suite - Taiwan - 2018-2024 - MedSuite (Includes 5 Reports)

Minimally Invasive Spinal Implant Market Report Suite - Taiwan - 2018-2024 - MedSuite (Includes 5 Reports)

The Taiwanese minimally invasive spinal implant market includes the markets for MIS interbody devices, MIS pedicle screws and MIS instrumentation. In 2017, the largest segment in the total MIS implant market was the MIS pedicle screw market segment.


EXECUTIVE SUMMARY
TAIWANESE MINIMALLY INVASIVE SPINAL IMPLANT MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 INTRODUCTION
2.1.1 Degenerative Disc Disease
2.1.1.1 Disc Herniation
2.1.1.2 Stenosis
2.1.1.3 Spondyloisthesis
2.1.1.4 Arthritis
2.1.2 Spinal Deformities
2.1.2.1 Scoliosis
2.1.2.2 Kyphosis and Lordosis
2.1.3 Trauma and Tumor
2.1.4 Vertebral Compression Fractures
2.1.4.1 Osteoporosis
2.1.4.2 Vertebral Compression Fractures
PRODUCT ASSESSMENT
3.1 INTRODUCTION
3.2 PRODUCT PORTFOLIOS
3.2.1 Cervical Fixation
3.2.1.1 Anterior Cervical Fixation
3.2.1.1.1 Constrained
3.2.1.1.2 Semi-Constrained
3.2.1.1.3 Dynamic
3.2.1.1.4 Bioresorbable
3.2.1.2 Posterior Cervical Fixation
3.2.2 Thoracolumbar Fixation
3.2.2.1 Traditional Systems
3.2.2.2 Minimally Invasive Systems
3.2.3 Interbody Devices
3.2.3.1 Approaches
3.2.3.1.1 ALIF
3.2.3.1.2 PLIF
3.2.3.1.3 TLIF
3.2.3.1.4 Minimally Invasive PLIF
3.2.3.1.5 Minimally Invasive TLIF
3.2.3.1.6 LLIF
3.2.3.1.7 OLIF
3.2.3.1.8 Cervical
3.2.3.1.9 VBR/Corpectomy
3.2.3.2 Materials
3.2.3.2.1 Metal
3.2.3.2.2 PEEK
3.2.3.2.3 Machined Bone Allograft
3.2.4 Motion Preservation Devices
3.2.4.1.1 Artificial Discs
3.2.4.1.2 Dynamic Stabilization
3.2.4.1.3 Nucleus Replacement
3.2.4.1.4 Facet Arthroplasty
3.2.5 Spinous Process Fixation
3.2.6 Facet Fixation
3.2.7 MIS Sacroiliac Joint Fusion
3.2.8 Vertebral Compression Fracture Devices
3.2.8.1.1 Percutaneous Vertebroplasty
3.2.8.1.2 Percutaneous Vertebral Augmentation Including Kyphoplasty
3.2.9 Spine Endoscopes
3.2.10 Spinal Electrical Stimulation Devices
3.3 FDA RECALLS
3.3.1 Alphatec Spine
3.3.2 DePuy Synthes
3.3.3 Medtronic
3.3.4 Orthofix
3.3.5 Stryker
3.3.6 Zimmer Biomet
3.4 CLINICAL TRIALS
3.4.1 DePuy Synthes
3.4.2 Globus Medical
3.4.3 K2M
3.4.4 Medtronic
3.4.5 Stryker
3.4.6 Zimmer Biomet
TAIWANESE MINIMALLY INVASIVE SPINAL IMPLANT MARKET OVERVIEW
4.1 INTRODUCTION
4.1.1 Minimally Invasive Interbody Fusion
4.1.1.1 Minimally Invasive Posterior Lumbar Interbody Fusion
4.1.1.2 Minimally Invasive Transforaminal Lumbar Interbody Fusion
4.1.1.3 Lateral Lumbar Interbody Fusion
4.1.1.4 Oblique Lumbar Interbody Fusion
4.1.2 Minimally Invasive Surgery Pedicle Screws
4.1.2.1 Percutaneous MIS Systems
4.1.2.2 Retractor-Based MIS Systems
4.2 CURRENCY EXCHANGE RATE
4.3 MARKET OVERVIEW
4.4 TREND ANALYSIS BY SEGMENT
4.5 DRIVERS AND LIMITERS
4.5.1 Market Drivers
4.5.2 Market Limiters
4.6 COMPETITIVE MARKET SHARE ANALYSIS
4.7 MERGERS AND ACQUISITIONS
4.8 COMPANY PROFILES
4.8.1 Alphatec Spine
4.8.2 DePuy Synthes
4.8.3 Globus Medical
4.8.4 K2M
4.8.5 Medtronic
4.8.6 Orthofix
4.8.7 Stryker
4.8.8 Zimmer Biomet
4.9 SWOT ANALYSIS
4.9.1 DePuy Synthes
4.9.2 DJO Global
4.9.3 Globus Medical
4.9.4 Joimax Gmbh
4.9.5 K2M Inc.
4.9.6 Karl Storz
4.9.7 Medtronic
4.9.8 Merit Medical Systems, Inc.
4.9.9 NuVasive
4.9.10 Orthofix
4.9.11 Paradigm Spine
4.9.12 Richard Wolf
4.9.13 SI-Bone
4.9.14 Spinal Kinetic
4.9.15 Stryker
4.9.16 Zimmer Biomet
PROCEDURE NUMBERS
5.1 INTRODUCTION
5.2 PROCEDURES
5.2.1 Minimally Invasive Spinal Procedures
5.2.2 MIS Interbody Device Procedures
5.2.2.1 Total MIS Interbody Device Procedures
5.2.2.1.1 Total Levels Treated by MIS Interbody Devices
5.2.2.2 MIPLIF Procedures
5.2.2.3 MITLIF Procedures
5.2.2.4 LLIF Procedures
5.2.2.5 OLIF Procedures
5.2.3 MIS Thoracolumbar Fixation Procedures
5.2.3.1 Total MIS Thoracolumbar Fixation Procedures
5.2.3.1.1 Total Levels Treated by Total MIS Pedicle Screws
5.2.3.2 Retractor MIS Thoracolumbar Fixation Procedures
5.2.3.3 Percutaneous MIS Thoracolumbar Fixation Procedures
MINIMALLY INVASIVE INTERBODY DEVICE MARKET
6.1 INTRODUCTION
6.1.1 Approach Types
6.1.1.1 Minimally Invasive Posterior Lumbar Interbody Fusion
6.1.1.2 Minimally Invasive Transforaminal Lumbar Interbody Fusion
6.1.1.3 Lateral Lumbar Interbody Fusion
6.1.1.4 Direct Lateral Interbody Fusion
6.1.1.5 eXtreme Lateral Interbody Fusion
6.1.1.6 Guided Lateral Interbody Fusion
6.1.1.7 Oblique Lateral Interbody Fusion
6.2 MARKET OVERVIEW
6.3 MARKET ANALYSIS AND FORECAST
6.3.1 Total MIS Interbody Device Market
6.3.2 MIPLIF Market
6.3.3 MITLIF Market
6.3.4 LLIF Market
6.3.5 OLIF Market
6.4 DRIVERS AND LIMITERS
6.4.1 Market Drivers
6.4.2 Market Limiters
6.5 COMPETITIVE MARKET SHARE ANALYSIS
MINIMALLY INVASIVE PEDICLE SCREW MARKET
7.1 INTRODUCTION
7.1.1 Percutaneous MIS Systems
7.1.2 Retractor-Based MIS Systems
7.2 MARKET OVERVIEW
7.3 MARKET ANALYSIS AND FORECAST
7.3.1 Total MIS Pedicle Screw Market
7.3.2 Retractor MIS Pedicle Screw Market
7.3.3 Percutaneous MIS Pedicle Screw Market
7.4 DRIVERS AND LIMITERS
7.4.1 Market Drivers
7.4.2 Market Limiters
7.5 COMPETITIVE MARKET SHARE ANALYSIS
MINIMALLY INVASIVE INSTRUMENTATION MARKET
8.1 INTRODUCTION
8.2 MARKET ANALYSIS AND FORECAST
8.3 DRIVERS AND LIMITERS
8.3.1 Market Drivers
8.3.2 Market Limiters
8.4 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX: COMPANY PRESS RELEASES
10.1 INTRODUCTION
10.2 PRESS RELEASES
10.2.1 Alphatec Spine
10.2.1.1 Alphatec Holdings Announces Board and Executive Leadership Changes
10.2.1.2 Alphatec Holdings Announces Third Quarter 2016 Revenue and Financial Results
10.2.1.3 Alphatec Holdings Announces Company Updates
10.2.1.4 Alphatec Holdings Announces Company Updates
10.2.1.5 Alphatec Holdings Completes Sale of International Business to Globus Medical
10.2.1.6 Alphatec Holdings Announces Sale of International Business to Globus Medical
10.2.1.7 Alphatec Holdings Announces Fourth Quarter and Full Year 2015 Revenue and Financial Results
10.2.1.8 Alphatec Holdings Announces Third Quarter 2015 Revenue and Financial Results
10.2.1.9 Alphatec Spine Announces Retirement of James R. Glynn From Its Board of Directors; Donald A. Williams Appointed Audit Committee Chairman
10.2.1.10 Preliminary Third Quarter 2015 Revenue Results in Advance of Attendance at the 30th Annual North American Spine Society (Nass) Meeting in Chicago, Illinois
10.2.1.11 Alphatec Spine Introduces New Titanium-Coated PEEK Interbody Fusion System
10.2.1.12 Alphatec Spine Launches Alphatec Neocore(TM) Osteoconductive Matrix in the U.S.
10.2.1.13 Alphatec's Less-Invasive Arsenal(TM) Cortical Bone Fixation System Successfully Used in Over 50 Patients
10.2.1.14 Alphatec's Arsenal(TM) Spinal Fixation System Further Expanded to Address Broader Market
10.2.1.15 Alphatec Holdings Announces Second Quarter 2015 Revenue and Financial Results
10.2.1.16 Alphatec Spine Announces Appointment of Donald A. Williams to its Board of Directors
10.2.1.17 Alphatec Holdings Announces First Quarter 2015 Revenue and Financial Results
10.2.1.18 Alphatec Holdings Announces Fourth Quarter and Full Year 2014 Revenue and Financial Results
10.2.2 DePuy Synthes
10.2.2.1 SYNFIX® Evolution Secured Spacer System Provides Superior Biomechanical Stability1 with Enhanced Instrumentation Designed for Surgical Efficiency
10.2.2.2 DePuy Synthes Companies Introduces Zero-Profile Plate with Allograft Spacer for Neck
10.2.2.3 DePuy Synthes Companies Launches Portable Spine Imaging System to Help Expand Access to Advanced Visualization and Improve Patient Outcomes
10.2.2.4 Johnson & Johnson Medical Devices Companies Value-Based Solutions Help Health Systems Address Proposed Mandatory CMS Plan for Episode Payment Models
10.2.2.5 New Hand System From DePuy Synthes Companies Designed to Address Patient and Surgeon Needs Through Innovation and Versatility
10.2.2.6 DePuy Synthes Announces Agreement with Materialise for 3D-Printed Titanium Cranio-Facial Implants
10.2.2.7 DePuy Synthes Companies Announces Acquisition of BioMedical Enterprises, Inc., A Leader in Small Bone Fixation
10.2.2.8 DEPUY SYNTHES COMPANIES ANNOUNCES NEW STRATEGIC ALLIANCE WITH EXPERTS IN BUNDLED PAYMENTS
10.2.2.9 DePuy Synthes Spine Introduces EXPEDIUM VERSE® Spinal System
10.2.2.10 DEPUY SYNTHES COMPANIES ANNOUNCES FIVE-YEAR COOPERATION AGREEMENT WITH THE AO FOUNDATION
10.2.2.11 DEPUY SYNTHES COMPANIES ENHANCES ADULT DEFORMITY OFFERING WITH FOUR NEW PRODUCTS AND A NEW EDUCATION SOLUTION
10.2.2.12 TWO NEW SOLUTIONS FROM DEPUY SYNTHES COMPANIES GO ‘BEYOND THE IMPLANT’ FOR ORTHOPAEDIC PATIENTS
10.2.2.13 NEW ADVANCED NAILING SYSTEM FROM DEPUY SYNTHES COMPANIES DESIGNED TO IMPROVE SURGICAL TREATMENT OF HIP FRACTURES
10.2.2.14 DEPUY SYNTHES COMPANIES ACQUIRES OLIVE MEDICAL CORPORATION
10.2.2.15 DEPUY SYNTHES SPINE ANNOUNCES EXPANDED INDICATION FOR SYNAPSE™ OCCIPITAL-CERVICAL-THORACIC (OCT) SYSTEM
10.2.3 Globus Medical
10.2.3.1 Globus Medical Reports Third Quarter 2016 Results
10.2.3.2 Globus Medical Launches QUARTEX™ OCT Stabilization System
10.2.3.3 Globus Medical Launches INDEPENDENCE MIS™, a Minimally Invasive ALIF Integrated Plate-Spacer
10.2.3.4 Globus Medical Completes Acquisition of Alphatec’s International Business
10.2.3.5 Globus Medical Announces the Acquisition of Alphatec’s International Business
10.2.3.6 Globus Medical Reports Second Quarter 2016 Results
10.2.3.7 Globus Medical Appoints Eric Ian Schwartz as Senior Vice President and General Counsel
10.2.3.8 Globus Medical Reports First Quarter 2016 Results
10.2.3.9 Globus Medical Reports Full Year and Fourth Quarter 2015 Results
10.2.3.10 Globus Medical Reports Preliminary Fourth Quarter and Full Year Record Sales Results
10.2.3.11 Globus Medical Reports Third Quarter 2015 Results
10.2.3.12 Globus Medical Announces Key Executive Changes
10.2.3.13 James R. Tobin, former CEO of Boston Scientific, Joins Globus Medical Board of Directors
10.2.3.14 Globus Medical Reports Second Quarter 2015 Results
10.2.3.15 Globus Medical Announces RISE®-L, an Expandable Lateral Interbody Fusion Device
10.2.3.16 Globus Medical Reports First Quarter 2015 Results
10.2.3.17 Globus Medical Appoints Daniel Scavilla as Senior Vice President and CFO
10.2.3.18 Globus Medical Reports Preliminary Fourth Quarter and Full Year Sales Results
10.2.4 K2M
10.2.4.1 K2M Group Holdings, Inc. Reports Third Quarter 2016 Financial Results with U.S. Revenue Growth of 17% year-over-year; Updates Fiscal Year 2016 Outlook
10.2.4.2 K2M Announces US Launch of Comprehensive 3D Solutions at the 2016 North American Spine Society Annual Meeting
10.2.4.3 K2M Expands 3D-Printed MIS CASCADIA™ Lateral Interbody System Featuring Lamellar 3D Titanium Technology™
10.2.4.4 K2M Expands MESA® Platform with FDA Clearance for Growing Spine Application
10.2.4.5 K2M Group Holdings, Inc. Reports Second Quarter 2016 Financial Results; Reaffirms Fiscal Year 2016 Outlook
10.2.4.6 Spine Publication Article Demonstrates K2M's MESA Rail™ Achieved Significantly Better Curve Correction in Treating Adolescent Idiopathic Scoliosis (AIS)
10.2.4.7 K2M Enhances 3D-Printed Spine Portfolio Following FDA Clearance of Two CASCADIA™ Interbody Systems Featuring Lamellar 3D Titanium Technology™
10.2.4.8 Research Supporting Favorable Findings on K2M's RAVINE® Lateral Access System to Be Presented at SpineWeek 2016
10.2.4.9 K2M Group Holdings, Inc. Reports First Quarter 2016 Financial Results, Led by U.S. Revenue Growth of 20% year-over-year, and Updates 2016 Outlook
10.2.4.10 K2M's MESA® Mini and DENALI® Mini Spinal Systems Receive Additional FDA Clearance for Posterior Cervical Spine Fixation
10.2.4.11 K2M Group Holdings, Inc. Reports Record Revenue for Fiscal Year 2015, with Complex Spine Growth of 17%
10.2.4.12 K2M Receives CE Mark for Its Next-Generation RHINE™ Cervical Disc System
10.2.4.13 K2M Group Holdings, Inc. Reports Preliminary Fourth Quarter and Full Year 2015 Financial Results With 17% Annual Growth
10.2.4.14 K2M Expands Minimally Invasive Spine Portfolio With Addition of Its CASCADIA™ Lateral Interbody System Featuring Lamellar Titanium Technology™
10.2.4.15 K2M Expands MIS Portfolio With Addition of Its EVEREST® Minimally Invasive XT Spinal System
10.2.4.16 K2M Group Holdings, Inc. Reports Third Quarter Revenue Growth of 16.7% in Constant Currency and Increases Fiscal Year 2015 Revenue Guidance Range
10.2.4.17 K2M to Unveil 3D Printed Lamellar Titanium Technology(TM) at the 2015 North American Spine Society Annual Meeting
10.2.4.18 K2M Announces U.S. Launch of the EVEREST(R) Deformity Spinal System at the Scoliosis Research Society 50th Annual Meeting
10.2.4.19 K2M Enhances PYRENEES(R) Product Family With the Addition of Its Mono Cervical Plate System
10.2.4.20 K2M Group Holdings, Inc. Reports U.S. Complex Spine Growth of 24% and Financial Results for the Second Quarter of Fiscal Year 2015
10.2.4.21 K2M Expands Presence in Asia With Six Product Launches in Singapore and Hong Kong and Announces Participation at the IMAST 2015 Conference
10.2.4.22 K2M Group Holdings, Inc. Reports Preliminary Second Quarter Financial Results Including Domestic Revenue Growth of 24%
10.2.4.23 K2M Launches the MESA(R) 2 Deformity Spinal System in the US
10.2.4.24 K2M Group Holdings, Inc. Appoints Michael Turpin to Board of Directors
10.2.4.25 K2M Group Holdings, Inc. Reports First Quarter Revenue Growth of 21% and First Quarter of Fiscal Year 2015 Financial Results; Complex Spine Growth of 19% Year-Over-Year
10.2.4.26 K2M Announces Enhanced Complex Spine Portfolio With Addition of Its Innovative NILE(TM) Alternative Fixation Spinal System
10.2.4.27 K2M Group Holdings Inc. Reports 2014 Revenue Growth of 18.5% Fourth Quarter and Full Year 2014 Financial Results; Fourth Quarter Complex Spine Growth of 20.5% Year-over-Year
10.2.4.28 K2M Receives FDA 510(k) Clearance for the Next Generation of Its Innovative Complex Spine MESA(R) Technology
10.2.4.29 K2M Group Holdings, Inc. Reports Preliminary Fourth Quarter and Full Year 2014 Financial Results, Including Q4 US Complex Spine Growth of 20%
10.2.5 Medtronic
10.2.5.1 Medtronic Announces U.S. Launch of Integrated Health Solutions with University Hospitals Agreement
10.2.5.2 Medtronic Reports Second Quarter Financial Results
10.2.5.3 Medtronic Releases FY16 Integrated Performance Report
10.2.5.4 MiniMed® Connect Mobile Accessory for Android Now Available from Medtronic
10.2.5.5 Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
10.2.5.6 Medtronic Reports First Quarter Financial Results
10.2.5.7 Medtronic Launches Revamped Minimally Invasive Spine Fusion Procedures
10.2.5.8 Medtronic Strengthens Commitment to Asia Pacific
10.2.5.9 Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
10.2.5.10 Medtronic Welcomes Karen L. Parkhill as Its New Chief Financial Officer
10.2.5.11 Medtronic Announces the Pricing Terms of Its Cash Tender Offer of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
10.2.5.12 Medtronic Announces the Early Results and Upsizing of Its Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
10.2.5.13 Medtronic Statement on U.S. Department of Treasury's Recent Temporary and Proposed Regulations
10.2.5.14 Medtronic Announces Cash Tender Offer for Up to $2.75 Billion Aggregate Purchase Price of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
10.2.5.15 Medtronic Reports Third Quarter Financial Results
10.2.6 NuVasive
10.2.6.1 NuVasive Reports Third Quarter 2016 Financial Results
10.2.6.2 NuVasive Appoints Joan Stafslien as Executive Vice President, General Counsel
10.2.6.3 NuVasive Receives FDA 510(k) Clearance Reinforcing Comprehensive Portfolio Supporting Pediatric, Adolescent and Adult Spinal Deformity Patients
10.2.6.4 NuVasive Names Jason M. Hannon President and Chief Operating Officer; Patrick S. Miles Assumes Role of Vice Chairman
10.2.6.5 NuVasive's MAGEC System Featured in Live Surgery Event at the Spine Hospital at NewYork-Presbyterian
10.2.6.6 NuVasive Secures CMS Add-On Payment for Innovative MAGEC System
10.2.6.7 Michael D. O'Halleran and Patrick S. Miles Elected to NuVasive Board of Directors
10.2.6.8 NuVasive Reports Second Quarter 2016 Financial Results
10.2.6.9 NuVasive to Feature Industry-Leading Portfolio at 23rd International Meeting on Advanced Spine Technologies
10.2.6.10 NuVasive Completes Acquistion of Biotronic NeuroNetwork
10.2.6.11 NuVasive Agrees to Settle Patent Litigation With Medtronic
10.2.6.12 NuVasive to Acquire Biotronic NeuroNetwork
10.2.6.13 NuVasive Launches Next Generation Biologics Technology
10.2.6.14 NuVasive Reports First Quarter 2016 Financial Results
10.2.6.15 NuVasive Launches Integrated Global Alignment (iGA(TM)) Platform at BritSpine 2016
10.2.6.16 NuVasive Announces Regulatory Approval of Reline(TM) Posterior Fixation Technology in Japan
10.2.6.17 NuVasive Announces Agreement to Acquire Brazilian Distributor Mega Surgical
10.2.6.18 NuVasive Elects Robert F. Friel and Donald J. Rosenberg to Board of Directors
10.2.6.19 NuVasive Reports Fourth Quarter and Full Year 2015 Financial Results
10.2.6.20 NuVasive Announces Select Preliminary Full-Year 2015 Financial Results and Reiterates 2016 Outlook
10.2.6.21 NuVasive to Acquire Ellipse Technologies
10.2.7 Orthofix
10.2.7.1 Orthofix Announces Appointment of Alex Lukianov to Board of Directors
10.2.7.2 Orthofix International Reports Third Quarter 2016 Financial Results
10.2.7.3 Orthofix International Reports Second Quarter 2016 Financial Results
10.2.7.4 Orthofix Announces Japanese Approval and Market Launch of PHOENIX Minimally Invasive Spinal Fixation System
10.2.7.5 Orthofix Announces 510(k) Clearance and US Limited Market Launch of FORZA PTC Interbody Spacer System
10.2.7.6 Orthofix International Reports First Quarter 2016 Financial Results
10.2.7.7 Orthofix Announces Appointment of Michael Paolucci to Board of Directors
10.2.7.8 Orthofix International Reports Fourth Quarter and Fiscal 2015 Financial Results
10.2.7.9 Orthofix Study Shows Pulsed Electromagnetic Field Therapy May Reduce Cellular Inflammation Associated with Disc Degeneration
10.2.7.10 Orthofix Announces Preliminary Fourth Quarter 2015 and Full Year Net Sales Results
10.2.7.11 Orthofix International Reports Third Quarter 2015 Financial Results
10.2.7.12 Orthofix Announces Publication of Data Confirming the Clinical Benefits of Trinity Evolution Cellular Bone Allograft in Foot and Ankle Procedures
10.2.7.13 Orthofix International Reports Second Quarter 2015 Financial Results
10.2.7.14 Orthofix Announces the Addition of Lilly Marks to Board of Directors
10.2.7.15 Orthofix International Reports First Quarter 2015 Financial Results
10.2.7.16 Orthofix International Reports Fourth Quarter and Fiscal 2014 Financial Results
10.2.7.17 Orthofix International Secures Option to Acquire eNeura, Inc.
10.2.7.18 Orthofix International Reports Third Quarter 2014 Results and Announces Filing of Restated Financial Statements
10.2.7.19 Orthofix International Provides Update Regarding NASDAQ Listing Matters
10.2.7.20 Orthofix International Announces Preliminary Net Sales Estimates for the 2014 and 2013 Fiscal Years and Updated Timing Objectives for Completion of Amended and Late Filings
10.2.8 Stryker
10.2.8.1 Stryker announces multi-year partnership with Indo UK Institute of Health to deliver affordable orthopaedic care in India
10.2.8.2 Stryker reports third quarter 2016 results
10.2.8.3 Stryker reports second quarter 2016 results
10.2.8.4 Stryker acquires Stanmore Implants Worldwide Limited
10.2.8.5 Stryker announces completion of the acquisition of vertebral compression fracture portfolio from BD
10.2.8.6 Stryker reports first quarter 2016 results
10.2.8.7 Stryker reports first quarter 2016 results
10.2.8.8 Stryker completes acquisition of Physio-Control International, Inc.
10.2.8.9 Stryker completes the acquisition of Synergetics USA, Inc.'s Neuro Portfolio
10.2.8.10 Stryker completes acquisition of Sage Products, LLC
10.2.8.11 Stryker Announces Definitive Agreement to Acquire Physio-Control International, Inc. for $1.28 Billion
10.2.8.12 Stryker Announces Definitive Agreement to Acquire Synergetics USA, Inc.'s Neuro Portfolio
10.2.8.13 Stryker Announces Definitive Agreement to Acquire Sage Products, LLC from Madison Dearborn Partners for $2.775 Billion
10.2.8.14 Stryker Announces the Retirement of William R. Jellison and the promotion of Glenn S. Boehnlein to Vice President, Chief Financial Officer
10.2.8.15 Stryker Reports 2015 Results and 2016 Outlook
10.2.8.16 Stryker Provides 2015 Preliminary Sales Results and Increases Adjusted Earnings Guidance
10.2.8.17 Stryker Reports Third Quarter 2015 Results
10.2.8.18 Stryker Completes Acquisition of Muka Metal, A.S.
10.2.8.19 Stryker Receives FDA Clearance For Mako Total Knee Application
10.2.8.20 Stryker Announces Definitive Agreement to Acquire Muka Metal, A.S.
10.2.8.21 Stryker Reports First Quarter 2015 Results
10.2.8.22 Stryker Reports 2014 Results and 2015 Outlook
10.2.8.23 Stryker Provides 2014 Preliminary Results and Updates 2015 Foreign Exchange Outlook
10.2.8.24 Stryker Acquires the Assets of CHG Hospital Beds, Inc.
10.2.9 Zimmer Biomet
10.2.9.1 Zimmer Biomet Strengthens Spine Offering with PrimaGen Advanced™ Allograft
10.2.9.2 Patient-matched glenoid implants allow surgeons to address extensive bone loss and deformities.
10.2.9.3 Zimmer Biomet Reports Positive Update on Biologics Pipeline Following a Preliminary Analysis of Data from the First Pivotal Trial of Stem Cell Therapy for Critical Limb Ischemia to Reach Completion
10.2.9.4 Zimmer Biomet Responsive Statement on Product Supply Matters
10.2.9.5 Zimmer Biomet Reports Third Quarter 2016 Financial Results
10.2.9.6 Zimmer Biomet Acquires RespondWell® Telerehabilitation Platform for Zimmer Biomet Signature Solutions
10.2.9.7 Zimmer Biomet Announces Positive Comparative Data from 7-Year Follow-Up Study of Mobi-C® Cervical Disc Prosthesis for Cervical Disc Replacement
10.2.9.8 Zimmer Biomet's Mobi-C® Cervical Disc Becomes Most Widely Covered Intervertebral Disc Prosthesis for Cervical Disc Replacement
10.2.9.9 Zimmer Biomet Expands Foot and Ankle Portfolio Through Exclusive Global Distribution Agreement with Nextremity Solutions, Inc.
10.2.9.10 Zimmer Biomet Adds 3D Range-of-Motion Simulation Capability with Strategic Acquisition of Clinical Graphics
10.2.9.11 Zimmer Biomet Strengthens Musculoskeletal Diagnostic Offering with Acquisition of CD Diagnostics
10.2.9.12 Zimmer Biomet Reports Second Quarter 2016 Financial Results
10.2.9.13 Zimmer Biomet Unveils Signature Solutions™
10.2.9.14 Zimmer Biomet Announces Multi-Year Collaboration with Indo UK Institutes of Health to Deliver Affordable and Accessible Healthcare in India
10.2.9.15 Zimmer Biomet Completes Tender Offer for Outstanding Shares of LDR Holding Corporation
10.2.9.16 Zimmer Biomet Celebrates Four Decades of Excellence with the 40th Anniversary of the Oxford® Partial Knee System
10.2.9.17 Zimmer Biomet Announces Early Termination of HSR Waiting Period
10.2.9.18 Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
10.2.9.19 Zimmer Biomet To Acquire LDR To Enhance Innovation And Growth Of Spine Business
10.2.9.20 Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2016
10.2.9.21 Zimmer Biomet Completes Acquisition of Cayenne Medical
10.2.9.22 Zimmer Biomet Holdings, Inc. Reports First Quarter 2016 Financial Results
10.2.9.23 Zimmer Biomet Enters into Definitive Agreement to Acquire Cayenne Medical
List of Charts
Chart 1 1: Minimally Invasive Spinal Implant Market by Segment, Taiwan, 2014 – 2024
Chart 1 2: Minimally Invasive Spinal Implant Market by Segment, Taiwan, 2017 & 2024
Chart 4 1: Minimally Invasive Spinal Implant Market by Segment, Taiwan, 2014 – 2024
Chart 4 2: Minimally Invasive Spinal Implant Market Breakdown, Taiwan, 2017
Chart 4 3: Minimally Invasive Spinal Implant Market Breakdown, Taiwan, 2024
Chart 4 4: Minimally Invasive Spinal Implant Market Growth by Segment, Taiwan, 2014 – 2024
Chart 4 5: Leading Competitors, Minimally Invasive Spinal Implant Market, Taiwan, 2017
Chart 5 1: Minimally Invasive Spinal Implant Procedures by Segment, Taiwan, 2014 – 2024
Chart 5 2: Total MIS Interbody Device Procedures by Segment, Taiwan, 2014 – 2024
Chart 5 3: Total MIS Thoracolumbar Fixation Procedures by Segment, Taiwan, 2014 – 2024
Chart 6 1: MIS Interbody Device Market by Segment, Taiwan, 2014 – 2024
Chart 6 2: MIS Interbody Device Market Breakdown, Taiwan, 2017
Chart 6 3: MIS Interbody Device Market Breakdown, Taiwan, 2024
Chart 6 4: Total MIS Interbody Device Market, Taiwan, 2014 – 2024
Chart 6 5: MIPLIF Market, Taiwan, 2014 – 2024
Chart 6 6: MITLIF Market, Taiwan, 2014 – 2024
Chart 6 7: LLIF Market, Taiwan, 2014 – 2024
Chart 6 8: OLIF Market, Taiwan, 2014 – 2024
Chart 6 9: Leading Competitors, MIS Interbody Device Market, Taiwan, 2017
Chart 7 1: MIS Pedicle Screw Market by Segment, Taiwan, 2014 – 2024
Chart 7 2: MIS Pedicle Screw Market Breakdown, Taiwan, 2017
Chart 7 3: MIS Pedicle Screw Market Breakdown, Taiwan, 2024
Chart 7 4: Total MIS Pedicle Screw Market, Taiwan, 2014 – 2024
Chart 7 5: Retractor MIS Pedicle Screw Market, Taiwan, 2014 – 2024
Chart 7 6: Percutaneous MIS Pedicle Screw Market, Taiwan, 2014 – 2024
Chart 7 7: Leading Competitors, MIS Pedicle Screw Market, Taiwan, 2017
Chart 8 1: MIS Instrumentation Market, Taiwan, 2014 – 2024
List of Figures
Figure 1 1: Minimally Invasive Spinal Implant Market Share Ranking by Segment, Taiwan, 2017
Figure 1 2: Companies Researched in this Report, Taiwan, 2017
Figure 1 3: Factors Impacting the Minimally Invasive Spinal Implant Market by Segment, Taiwan
Figure 1 4: Recent Events in the Minimally Invasive Spinal Implant Market, Taiwan, 2015 – 2018
Figure 1 5: Minimally Invasive Spinal Implant Procedures Covered, Taiwan, 2017
Figure 1 6: Minimally Invasive Spinal Implant Markets Covered, Taiwan, 2017
Figure 1 7: Key Report Updates
Figure 1 8: Version History
Figure 3 1: Cervical Fixation Devices by Company (1 of 2)
Figure 3 2: Cervical Fixation Devices by Company (2 of 2)
Figure 3 3: Thoracolumbar Fixation Devices by Company (1 of 2)
Figure 3 4: Thoracolumbar Fixation Devices by Company (2 of 2)
Figure 3 5: Interbody Devices by Company (1 of 2)
Figure 3 6: Interbody Devices by Company (2 of 2)
Figure 3 7: Cervical Artificial Disc Devices by Company
Figure 3 8: Lumbar Artificial Disc Devices by Company
Figure 3 9: Dynamic Posterior Stabilization Devices by Company
Figure 3 10: Interspinous Process Decompression Devices by Company
Figure 3 11: Spinous Process Fixation Devices by Company
Figure 3 12: Facet Fixation Devices by Company
Figure 3 13: MIS Sacroiliac Joint Devices by Company
Figure 3 14: Vertebral Compression Fracture Devices by Company
Figure 3 15: Spine Endoscopes by Company
Figure 3 16: Spinal Electrical Stimulation Devices by Company
Figure 3 17: Class 2 Device Recall Alphatec Spine
Figure 3 18: Class 2 Device Recall DePuy Synthes
Figure 3 19: Class 2 Device Recall DePuy Synthes
Figure 3 20: Class 2 Device Recall Medtronic
Figure 3 21: Class 2 Device Recall Medtronic
Figure 3 22: Class 2 Device Recall Medtronic
Figure 3 23: Class 2 Device Recall Medtronic
Figure 3 24: Class 2 Device Recall Orthofix
Figure 3 25: Class 2 Device Recall Orthofix
Figure 3 26: Class 2 Device Recall Orthofix
Figure 3 27: Class 2 Device Recall Orthofix
Figure 3 28: Class 2 Device Recall Stryker
Figure 3 29: Class 2 Device Recall Stryker
Figure 3 30: Class 2 Device Recall Zimmer Biomet
Figure 3 31: An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix
Figure 3 32: A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.
Figure 3 33: Comparing Pedicle Screw Systems for the Treatment of Adolescent Paediatric Spine Deformity
Figure 3 34: A Prospective, 5-Year Global Study on MAST™
Figure 3 35: Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation (SCS-PAF)
Figure 3 36: OLIF25™ /OLIF51™ Study
Figure 3 37: AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY (APROPOS)
Figure 3 38: Post-Market Surveillance Study of the TM Ardis Interbody Fusion System
Figure 4 1: Currency Exchange

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report